The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium
Open accessAbstract
The COVID-19 pandemic presents clinicians a unique set of challenges in managing breast cancer (BC) patients. As hospital resources and staff become more limited during the COVID-19 pandemic, it becomes critically important to define which BC patients require more urgent care and which patients can wait for treatment until the pandemic is over. In this Special Communication, we use expert opinion of representatives from multiple cancer care organizations to categorize BC patients into priority levels (A, B, C) for urgency of care across all specialties. Additionally, we provide treatment recommendations for each of these patient scenarios. Priority A patients have conditions that are immediately life threatening or symptomatic requiring urgent treatment. Priority B patients have conditions that do not require immediate treatment but should start treatment before the pandemic is over. Priority C patients have conditions that can be safely deferred until the pandemic is over. The implementation of these recommendations for patient triage, which are based on the highest level available evidence, must be adapted to current availability of hospital resources and severity of the COVID-19 pandemic in each region of the country. Additionally, the risk of disease progression and worse outcomes for patients need to be weighed against the risk of patient and staff exposure to SARS CoV-2 (virus associated with the COVID-19 pandemic). Physicians should use these recommendations to prioritize care for their BC patients and adapt treatment recommendations to the local context at their hospital.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
Whelan, T. J., Pignol, J.-P., Levine, M. N., Julian, J. A., MacKenzie, R., Parpia, S., Shelley, W., Grimard, L., Bowen, J., Lukka, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0906260 · Cited by 1,878
Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer
Ragaz, J., Jackson, S. M., Le, N., Plenderleith, I. H., Spinelli, J. J., Basco, V. E., Wilson, K. S., Knowling, M. A., Coppin, C. M. L., Paradis, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710023371402 · Cited by 1,745
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Self-citationHaviland, J. S., Owen, J. R., Dewar, J. A., Agrawal, R. K., Barrett, J., Barrett-Lee, P. J., Dobbs, H. J., Hopwood, P., Lawton, P. A., Magee, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70386-3 · Cited by 1,470
Hughes, K. S., Schnaper, L. A., Bellon, J. R., Cirrincione, C. T., Berry, D. A., McCormick, B., Muss, H. B., Smith, B. L., Hudis, C. A., Winer, E. P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2615 · Cited by 1,310
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Palliative Radiotherapy Trials for Bone Metastases: A Systematic Review
Chow, E., Harris, K., Fan, G., Tsao, M., & Sze, W. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.5281 · Cited by 908
Cited by
Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., Senn, H. J., Winer, E. P., Gnant, M., Aebi, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 821
Self-citationAl-Shamsi, H. O., Alhazzani, W., Alhuraiji, A., Coomes, E. A., Chemaly, R. F., Almuhanna, M., Wolff, R. A., Ibrahim, N. K., Chua, M. L. K., Hotte, S. J., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0213 · Cited by 694
Wang, S.-L., Fang, H., Song, Y.-W., Wang, W.-H., Hu, C., Liu, Y.-P., Jin, J., Liu, X.-F., Yu, Z.-H., Ren, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30813-1 · Cited by 396
Glasbey, J., Ademuyiwa, A., Adisa, A., AlAmeer, E., Arnaud, A. P., Ayasra, F., Azevedo, J., Minaya-Bravo, A., Costas-Chavarri, A., Edwards, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00493-9 · Cited by 287
Cancer treatment and survivorship statistics, 2025
Wagle, N. S., Nogueira, L., Devasia, T. P., Mariotto, A. B., Yabroff, K. R., Islami, F., Jemal, A., Alteri, R., Ganz, P. A., & Siegel, R. L. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.70011 · Cited by 261
Metadata
- Authors
- Dietz, J. R., Moran, M. S., Isakoff, S. J., Kurtzman, S. H., Willey, S. C., Burstein, H. J., Bleicher, R. J., Lyons, J. A., Sarantou, T., Baron, P. L., Stevens, R. E., Boolbol, S. K., Anderson, B. O., Shulman, L. N., Gradishar, W. J., Monticciolo, D. L., Plecha, D. M., Nelson, H., & Yao, K. A.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2020-04-24
- Volume
- 181
- Issue
- 3
- Pages
- 487-497
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W3018098307
- Cited by
- 393
- References
- 38
- FWCI
- 27.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. https://app.cochat.ai/papers/10.1007/s10549-020-05644-z
- The paper
- Dietz, J. R., Moran, M. S., Isakoff, S. J., Kurtzman, S. H., Willey, S. C., Burstein, H. J., Bleicher, R. J., Lyons, J. A., Sarantou, T., Baron, P. L., Stevens, R. E., Boolbol, S. K., Anderson, B. O., Shulman, L. N., Gradishar, W. J., Monticciolo, D. L., Plecha, D. M., Nelson, H., & Yao, K. A. (2020). Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-020-05644-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.